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Sir, 66 
a systematic review has reported that, in Crohns’ disease (CD) patients, the prevalence of cholelithiasis ranged 67 
from 11% to 34%, that of primary sclerosing cholangitis (PSC) from 1.2% to 3.4%, that of fatty liver 68 
disease 23% and hepatic amyloidosis occurred in <1% [1]. In a prospective, single-blind study we evaluated the 69 
prevalence of histological changes in the liver of patients with CD, without alterations of both liver biochemical 70 
tests and ultrasound, and their prognostic significance. The patients underwent liver biopsy at the time of 71 
intestinal resection. Exclusion criteria were a known liver disease. Thereafter, patients were clinically monitored 72 
every 6 months, upper abdomen ultrasound was performed at least every 12 months. Finally, after a mean 73 
interval of 14 years from liver biopsy, these patients were assessed using the Fibroscan® (Echosens®, Paris, 74 
France). Ultrasound examination in the pre-operative step showed steatosis in 10 (29%) patients. At biopsy 75 
specimens alterations in 60% of patients, without serious liver injuries, were found. No evidence of a significant 76 
liver damage progression after a mean period of 14 years were found. The average result (5.2 ± 1.2 kPa) 77 
obtained performing Fibroscan® was comparable to that (5.30 ± 1.45 kPa, p = 0.63) reported in healthy subjects 78 
[2].  79 
A recent interesting retrospective study  was performed in 383 CD patients newly diagnosed (not treated). One 80 
patient with chronic liver disease (small duct PSC) was excluded. Of the 383 patients included in this study, 131 81 
had liver test abnormalities (34.1%), but liver diseases were not found, apart from liver steatosis in 6% of 82 
patients [3] (versus 29% in the previous study [2]).  83 
The two studies [2, 3] agree that, considering the cost/benefit ratio, patients with CD should be considered as 84 
healthy from the liver perspective, without the need for additional biochemical and instrumental examinations 85 
than the general population, unless the presence of clinical or biochemical suspicion of liver disease. 86 
In the more recent study [3], however, the authors found that, patients with liver test abnormalities, without an 87 
hepatic disease, more often developed complicated CD behaviour and more often  needed hospitalization or 88 
surgery within 5 years of diagnosis than patients without liver test abnormalities. Patients with a C-reactive 89 
protein (CRP) <16 mg/L but with liver test abnormalities had a higher risk of developing complicated disease 90 
compared to those without liver test abnormalities. This demonstrates that the presence of liver test abnormalities 91 
does not merely reflect a higher CRP concentration, but may be a more sensitive indicator of an increased risk of 92 
complicated disease behaviour than CRP. At multivariate analysis, the presence of liver test abnormalities was 93 
independent risk factors for complicated disease behaviour; additionally, the presence of liver test abnormalities 94 
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was independently associated with an increased risk of hospitalizations (HR 1.7, p = 0.023) as well as surgery 95 
(HR 2.3, p = 0.015) [3][]. 96 
In conclusion, in the absence of a known liver disease or of a risk factor for hepatic injury (e.g., a potentially 97 
hepatotoxic drugs), liver enzymes in CD do not need to be routinary measured. However, when increased, liver 98 
enzymes could predict a more aggressive CD behaviour. 99 
100 
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